Skip to main content
Clinical Trials/EUCTR2017-004297-34-GB
EUCTR2017-004297-34-GB
Active, not recruiting
Phase 1

A placebo controlled double blind randomised controlled proof of concept study of zolpidem for the treatment of motor and cognitive deficits in late-stage Parkinson’s - Zolpidem for treatment of motor and cognitive deficits in Parkinson's

Aston University0 sites28 target enrollmentJune 22, 2018

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Aston University
Enrollment
28
Status
Active, not recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 22, 2018
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of idiopathic Parkinson’s and Hoehn and Yahr score of 2\.5 or more.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 14
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range 14

Exclusion Criteria

  • Under the age of 40 years.
  • Over the age of 80 years.
  • Unable or unwilling to give informed consent
  • Current therapy with CNS depressants
  • Current therapy with CPY450 (CYP3A4\) inhibitors or inducers
  • History of psychiatric disorders
  • History of alcohol or substance abuse
  • Employed in a role that involves driving or operating heavy machinery
  • Participating in another interventional clinical trial

Outcomes

Primary Outcomes

Not specified

Similar Trials